Yong Zang, PhD

Key Publications

Recent Methdological Publications († for corresponding author, ‡ for supervised student):

1. Guo J‡, Lu M, Wan I, Wang Y, Han L and Zang Y†. T3+3: 3+3 designs with dealyed outcomes. Pharmaceutical Statistics accepted, 2024.
2. Zang Y†, Thall P and Yuan Y. A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80: ujad022, 2024.
3. Park J, Hu W, Jin IH, Liu H and Zang Y†. A Bayesian adaptive biomarker stratified phase II randomized clinical trial design for radiotherapies with competing risks survival outcomes. Statistical Methods in Medical Research 33: 80-95, 2024.
4. Zang Y†, Guo B, Qiu Y‡, Liu H, Opyrchal M and Lu X. Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical Trials 21: 298-307, 2024. (Invited review paper)
5. Chen W‡, Ding Z, Zang Y and Liu X. Characterization of proteoform post-translational modifications by top-down and bottom-up mass spectrometry in conjunction with UniProt annotations. Journal of Proteome Research 22: 3178-3189, 2023.
6. Thall P, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D and Msaouel P. Novel clinical trial designs that optimize dose to improve long-term outcomes. Clinical Cancer Research 29: 4549-4554, 2023.
7. Basharat AR‡, Zang Y, Sun L and Liu X. TopFD: A proteoform feature detection tool for top-down proteomics. Analytical Chemistry 95: 8189-8196, 2023.
8. Thall P, Zang Y and Yuan Y. Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical Statistics 22: 692-706, 2023.
9. Qiu Y‡, Zhao Y, Liu H, Cao S, Zhang C and Zang Y†. Modified isotonic regression based phase I/II clinical trial design identifying optimal biological dose. Contemporary Clinical Trials 127: 107139, 2023.
10. Shan M‡, Guo B, Liu H, Li Q and Zang Y†. Bayesian order constrained adaptive design for phase II clinical trials evaluating subgroup-specific treatment effect. Statistical Methods in Medical Research 32: 885-894, 2023.
11. Guo B, Zang Y, Lin H and Zhang R. A Bayesian phase I/II design to determine subgroup-specific optimal dose for immunotherapy sequentially combined with radiotherapy. Pharmaceutical Statistics 22: 143-161, 2023.
12. Chen W‡, McCool E, Sun L, Zang Y, Ning X, Liu, X. Evaluation of machine learning models for proteoform retention and migration time prediction in top-down mass spectrometry. Journal of Proteome Research 21: 1736-1747, 2022.
13. Zhang Y‡, Guo B, Cao S, Zhang C and Zang Y†. SCI: A Bayesian adaptive phase I/II dose-finding design accounting for semi-competing risks outcomes for immunotherapy trials. Pharmaceutical Statistics 21: 960-973, 2022 (Top cited article 2022-2023).
14. Guo B and Zang Y. A Bayesian phase I/II biomarker-based design for identifying subgroup-specific optimal dose for immunotherapy. Statistical Methods in Medical Research 31: 1104-1119, 2022.
15. Guo B and Zang Y. BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint. Statistics in Medicine 41: 1205-1224, 2022.
16. Chen Z and Zang Y†. CMAX3: A robust statistical test for genetic association accounting for covariates. Genes 12: 1723, 2021.
17. Zhang Y‡ and Zang Y†. CWL: A conditional weighted likelihood method to account for the delayed joint toxicity-efficacy outcomes for phase I/II clinical trials. Statistical Methods in Medical Research 30: 892-903, 2021.
18. Han Y, Liu H, Cao S, Zhang C and Zang Y†. TSNP: a two-stage nonparametric phase I/II clinical trial design for immunotherapy. Pharmaceutical Statistics 20: 282-296, 2021.
19. Guo B and Zang Y. BILITE: A Bayesian phase II design for immunotherapy by jointly modeling the longitudinal immune response and time-to-event efficacy. Statistics in Medicine 39: 4439-4451, 2021.
20. Zhang Y‡, Cao S, Zhang C, Jin IH and Zang Y†. A Bayesian adaptive phase I/II clinical trial design with late-onset competing risk outcomes. Biometrics 77: 796-808, 2021 (Top cited article 2020-2021, 2021-2022).